2026 Global: Cell Dissociation Market-Competitive Review (2032) report
Description
The 2026 Global: Cell Dissociation Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cell dissociation market by geography and historical trend. The scope of the report extends to sizing of the cell dissociation market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The cell dissociation market features ten major companies driving innovation in enzymatic reagents, automated instruments, and tissue-specific kits amid surging demand from biopharmaceutical R&D and cell therapies. Leading players include Thermo Fisher Scientific, which dominates with broad reagent portfolios like Gibco TrypLE and recent enzyme kits for neural tissues, enhancing cell viability for drug discovery. Roche Holding AG (F. Hoffmann-La Roche Ltd.) excels in precision dissociation solutions integrated with diagnostic platforms, supporting clinical trials through scalable enzymatic products. Danaher Corporation leverages subsidiaries like Beckman Coulter for high-throughput automation, bolstering efficiency in regenerative medicine workflows. Becton Dickinson and Company (BD) advances mechanical dissociators and compatible tools for oncology trials, ensuring high-volume tissue processing with minimal cell damage. Miltenyi Biotec pioneers MACS technology in gentleMACS systems and kits, enabling GMP-compliant, tissue-tailored dissociation for single-cell analysis and immunotherapy.
Merck KGaA supplies versatile enzymatic blends like collagenase alongside non-enzymatic options, fueling biomanufacturing with consistent yields for gene therapy pipelines. STEMCELL Technologies specializes in optimized kits combining enzymatic and mechanical methods for challenging tissues like tumors, prioritizing viability in personalized medicine applications. Sartorius AG innovates with CellCelector platforms and automation for end-to-end cell processing, reducing labor in high-throughput labs. HiMedia Laboratories provides cost-effective, regulatory-compliant reagents for global CROs, supporting expanding biopharma in Asia-Pacific. These firms capitalize on market growth projected from $455-710 million in 2025 to $1.6-2.2 billion by 2034-2035, driven by single-cell omics and AI integration.
GE HealthCare Technologies Inc. contributes imaging-compatible dissociation tools for advanced research, while Bio-Techne Corporation targets rare cell isolation with stress-minimizing reagents critical for cancer immunotherapy. Lonza Group AG, Corning Incorporated, and Bio-Rad Laboratories Inc. further strengthen the landscape with specialized accessories and scalability solutions for industrial cell culture. Intense competition spurs innovations like Thermo Fisher's 5L bioreactors and Miltenyi's upgraded dissociators, as North America leads with 39% share, propelled by biotech investments. CROs grow fastest at 18.65% CAGR, outsourcing amid sponsor constraints, while Asia-Pacific accelerates via infrastructure expansion. Overall, these companies navigate enzyme shortages through long-term contracts and microfluidics, ensuring reproducible, high-yield dissociation for chronic disease research and vaccines.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cell dissociation market by geography and historical trend. The scope of the report extends to sizing of the cell dissociation market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The cell dissociation market features ten major companies driving innovation in enzymatic reagents, automated instruments, and tissue-specific kits amid surging demand from biopharmaceutical R&D and cell therapies. Leading players include Thermo Fisher Scientific, which dominates with broad reagent portfolios like Gibco TrypLE and recent enzyme kits for neural tissues, enhancing cell viability for drug discovery. Roche Holding AG (F. Hoffmann-La Roche Ltd.) excels in precision dissociation solutions integrated with diagnostic platforms, supporting clinical trials through scalable enzymatic products. Danaher Corporation leverages subsidiaries like Beckman Coulter for high-throughput automation, bolstering efficiency in regenerative medicine workflows. Becton Dickinson and Company (BD) advances mechanical dissociators and compatible tools for oncology trials, ensuring high-volume tissue processing with minimal cell damage. Miltenyi Biotec pioneers MACS technology in gentleMACS systems and kits, enabling GMP-compliant, tissue-tailored dissociation for single-cell analysis and immunotherapy.
Merck KGaA supplies versatile enzymatic blends like collagenase alongside non-enzymatic options, fueling biomanufacturing with consistent yields for gene therapy pipelines. STEMCELL Technologies specializes in optimized kits combining enzymatic and mechanical methods for challenging tissues like tumors, prioritizing viability in personalized medicine applications. Sartorius AG innovates with CellCelector platforms and automation for end-to-end cell processing, reducing labor in high-throughput labs. HiMedia Laboratories provides cost-effective, regulatory-compliant reagents for global CROs, supporting expanding biopharma in Asia-Pacific. These firms capitalize on market growth projected from $455-710 million in 2025 to $1.6-2.2 billion by 2034-2035, driven by single-cell omics and AI integration.
GE HealthCare Technologies Inc. contributes imaging-compatible dissociation tools for advanced research, while Bio-Techne Corporation targets rare cell isolation with stress-minimizing reagents critical for cancer immunotherapy. Lonza Group AG, Corning Incorporated, and Bio-Rad Laboratories Inc. further strengthen the landscape with specialized accessories and scalability solutions for industrial cell culture. Intense competition spurs innovations like Thermo Fisher's 5L bioreactors and Miltenyi's upgraded dissociators, as North America leads with 39% share, propelled by biotech investments. CROs grow fastest at 18.65% CAGR, outsourcing amid sponsor constraints, while Asia-Pacific accelerates via infrastructure expansion. Overall, these companies navigate enzyme shortages through long-term contracts and microfluidics, ensuring reproducible, high-yield dissociation for chronic disease research and vaccines.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
